Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : J&J Offered to Pay $4 Billion to Resolve Talc Cancer Claims Months Before Unit Bankruptcy

10/21/2021 | 03:02pm EST


© MT Newswires 2021
All news about JOHNSON & JOHNSON
10:37aLegend Biotech Submits New Drug Application for Myeloma CAR-T Therapy to Japanese Regul..
MT
08:32aJohnson & Johnson Unit's Respiratory Syncytial Virus Vaccine Candidate Shows Up to 80% ..
MT
07:16aJ&J'S JANSSEN : Phase 2b RSV Vaccine Study Meets All Endpoints
DJ
05:45aJohnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of t..
AQ
05:07aCORONAVIRUS-MOZAMBIQUE : The United States Donates Additional 2 Million Johnson & Johnson ..
AQ
12/06CORONAVIRUS-MOZAMBIQUE : The United States Donates Additional 2 Million Johnson & Johnson ..
AQ
12/06Legend Biotech Submits New Drug Application for Myeloma Therapy to Japanese Regulator
MT
12/06Kaleido Biosciences Expands and Extends Collaboration With Janssen
MT
12/06Johnson & Johnson - Latest Phase 3 Data for First-in-Class TREMFYA Demonstrates Signifi..
AQ
12/06J&J Says Its 'Mix-and-Match' COVID-19 Booster With Pfizer Vaccine Shows Increase in Ant..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 19,7x
Yield 2021 2,56%
Capitalization 429 B 429 B -
EV / Sales 2021 4,56x
EV / Sales 2022 4,24x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 162,94 $
Average target price 184,65 $
Spread / Average Target 13,3%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321
ABBVIE INC.10.92%214 532